MedTrace Logo

Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy

NCT00721591 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2016-11-01

No results posted yet for this study

Summary

To determine, through pharmacokinetic parameters, the ideal dosing protocol for dalteparin (a low molecular weight heparin) and unfractionated heparin for women desiring pregnancy who have evidence of an acquired (specifically, antiphospholipid syndrome) or inherited thrombophilia.

Conditions

  • Recurrent Pregnancy Loss
  • Fetal Demise
  • Abortion, Habitual
  • Antiphospholipid Antibodies
  • Inherited Thrombophilia

Sponsors & Collaborators

  • University of British Columbia

    collaborator OTHER

  • University of Chicago

    lead OTHER

Principal Investigators

  • Mary D. Stephenson, MD, MSc · University of Chicago

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2013-01-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00721591 on ClinicalTrials.gov